Nanotechnology Now - News Story: "Quantum Dot Corporation Awarded $2 Million"

Home > News > Quantum Dot Corporation Awarded $2 Million

September 29th, 2004

Quantum Dot Corporation Awarded $2 Million

Abstract:
Quantum Dot Corp. (QDC) announced the award of a $2 million grant from the National Institute of Standards and Technology under its Advanced Technology Program (ATP). Clinical grade quantum dots will be developed with initial applications in ocular and cancer imaging.

Story:

Quantum Dot Corporation Awarded $2 Million

NIST ATP Grant to develop clinical grade quantum dots for human imaging

Hayward, CA, September 29, 2004

Quantum Dot Corp. (QDC) announced the award of a $2 million grant from the National Institute of Standards and Technology under its Advanced Technology Program (ATP). Clinical grade quantum dots will be developed with initial applications in ocular and cancer imaging.

Quantum dot nanocrystal technology enables dramatically improved visualization of biological events in diverse areas of drug discovery research and in vitro diagnostics. Peer-reviewed studies using Qdot® nanocrystal products, commercially launched in late 2002, led to recognition of quantum dot bio-imaging as one of Science magazine's top 10 scientific breakthroughs of 2003. Quantum dots are nanoscale crystals of semiconductors that behave as single "super atoms." The new ATP funded development work will be the first step in developing human clinical imaging products that are enabled by the unique optical properties of quantum dot nanocrystals.

"These next-generation quantum dots will allow, for the first time, direct imaging of small numbers of dying cells in degenerative eye diseases, and reduce the time frame for testing ocular drugs from 10 years to less than one," stated QDC scientist Joe Treadway, PhD, principal investigator for the grant. "These new materials also will greatly enhance imaging during surgical removal of lymph nodes associated with cancerous tumors, thereby improving the prognosis for cancer patients and saving lives while simultaneously reducing the cost and training required for the procedures."

"This prestigious award is a further validation of the strength of our world-class scientific team," commented George Dunbar, CEO of QDC. "Our investment in our core quantum dot technology will drive significant future value creation in clinical applications."

QDC's award is one of 32 ATP awards in 2004. These were selected in an open competition from 870 applications. Manufacturing scale up technology will also be developed, enabling additional spin-off benefits in a range of consumer products such as bright, low-power electronic displays, and bright white light-emitting diodes. Additional information available here.

About Quantum Dot Corporation

Quantum Dot is a privately held bioscience company that has pioneered the development and commercialization of Qdot® nanocrystals for bio-detection in discovery and clinical applications. QDC will soon be launching its first integrated instrumentation, software, and bio-reagents platform, the Mosaic™ system, for rapid and quantitative multiplexed gene expression analysis. QDC's current products include life science kits and applications, used by academic and pharmaceutical discovery laboratories worldwide. QDC collaborates with leading academic and industrial partners and has over 130 patents and patents-pending. For more information, visit www.qdots.com.

About the Advanced Technology Program

The Advanced Technology Program, managed by the National Institute of Standards and Technology, provides cost-shared funding to industry for high-risk R&D projects with the potential to spark important, broad-based economic benefits for the United States. The awards are made on the basis of a rigorous peer-reviewed selection process. For more information, visit the ATP web site.

Contact:
George Dunbar
CEO, Quantum Dot Corporation
(510) 887 8775, ext. 4101

Joe Treadway
Principal Scientist, Quantum Dot Corporation
(510) 887 8775, ext. 4123

Copyright © Quantum Dot Corporation

If you have a comment, please us.

Bookmark: